Avdoralimab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Avdoralimab is a monoclonal antibody that targets the C5a receptor, a component of the complement system involved in inflammation and immune response. It is being investigated for its potential therapeutic effects in various inflammatory and autoimmune diseases.
Mechanism of Action[edit | edit source]
Avdoralimab works by binding to the C5a receptor (C5aR1), which is a G protein-coupled receptor expressed on the surface of various immune cells, including neutrophils and macrophages. The binding of Avdoralimab to C5aR1 inhibits the interaction of the receptor with its natural ligand, C5a, a potent inflammatory peptide. This inhibition reduces the recruitment and activation of inflammatory cells, thereby decreasing inflammation and tissue damage.
Clinical Development[edit | edit source]
Avdoralimab is currently under investigation in clinical trials for its efficacy and safety in treating conditions such as rheumatoid arthritis, systemic lupus erythematosus, and COVID-19-related complications. Early studies have shown promising results in reducing inflammatory markers and improving clinical outcomes in patients with these conditions.
Potential Applications[edit | edit source]
The therapeutic potential of Avdoralimab extends to a variety of diseases characterized by excessive or dysregulated complement activation. These include:
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Ankylosing spondylitis
- COVID-19-related acute respiratory distress syndrome (ARDS)
Safety and Efficacy[edit | edit source]
The safety profile of Avdoralimab is being closely monitored in clinical trials. Common adverse effects observed include mild to moderate infusion-related reactions. The efficacy of Avdoralimab is measured by its ability to reduce disease activity scores and improve patient-reported outcomes.
Research and Development[edit | edit source]
Avdoralimab is developed by Innate Pharma, a biotechnology company focused on developing immunotherapies for cancer and inflammatory diseases. The development of Avdoralimab is part of a broader effort to target the complement system as a therapeutic strategy.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
